Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556924 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL487870 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11331724 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL8845927 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL332105 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL332501 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL488468 | 1.00 | TSHR (0.57) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Ammonia Solution, Strong SCHEMBL19874805 | 0.97 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11524980 | 0.96 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL88650 | 0.96 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156954-B2 | Composition for hard tissue repair and kit for hard tissue repair | MITSUI CHEMICALS, INC. (JP) | 2024-12-03 | — | — | US | disclosed |
| EP-3603685-B1 | COMPOSITION FOR REPAIRING HARD TISSUE AND KIT FOR REPAIRING HARD TISSUE | MITSUI CHEMICALS INC (JP) | 2024-10-23 | — | — | EP | disclosed |
| EP-3769795-B1 | HARD TISSUE REPAIR COMPOSITION AND HARD TISSUE REPAIR KIT | MITSUI CHEMICALS INC (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-11883555-B2 | Composition for hard tissue repair and kit for hard tissue repair | MITSUI CHEMICALS, INC. (JP) | 2024-01-30 | — | — | US | disclosed |
| EP-3603684-B1 | HARD TISSUE REPAIR COMPOSITION AND HARD TISSUE REPAIR KIT | MITSUI CHEMICALS INC (JP) | 2023-03-22 | — | — | EP | disclosed |
| CN-110461377-B | Composition for hard tissue repair and kit for hard tissue repair | 三井化学株式会社 | 2022-05-10 | — | — | CN | disclosed |
| CN-110461379-B | Composition for hard tissue repair and kit for hard tissue repair | 三井化学株式会社 | 2022-05-10 | — | — | CN | disclosed |
| US-11311642-B2 | Composition for hard tissue repair and kit for hard tissue repair | MITSUI CHEMICALS, INC. (JP) | 2022-04-26 | — | — | US | disclosed |
| CN-111867640-B | Composition for hard tissue repair and kit for hard tissue repair | 三井化学株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-20210023260-A1 | COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR | MITSUI CHEMICALS, INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20010051587-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | WESTLAKE LONGVIEW CORPORATION | 2001-12-13 | — | — | US | disclosed |
| US-20010031841-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | WESTLAKE LONGVIEW CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-20010029286-A1 | Procatalysts, catalyst systems, and use in OLEFIN polymerization | EASTMAN CHEMICAL COMPANY, A CORP. OF DELAWARE | 2001-10-11 | — | — | US | disclosed |
| US-20010025005-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | EASTMAN CHEMICAL COMPANY, A CORPORATION OF DELAWARE | 2001-09-27 | — | — | US | disclosed |
| WO-2001051527-A1 | PROCATALYSTS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051526-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051529-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0578473-B1 | Catalyst for polymerization of olefin and process for producing olefin polymer | SHOWA DENKO KK (JP) | 1997-11-19 | — | — | EP | disclosed |
| US-5476825-A | Consists of magnesium, titanium and halogen compounds, an organoaluminum compound, a reaction product of organoaluminum or organoboron compound with organosilicon compound | SHOWA DENKO K.K. (JP) | 1995-12-19 | — | — | US | disclosed |
| EP-0578473-A1 | Catalyst for polymerization of olefin and process for producing olefin polymer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023260-A1 | COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR | RAD51, CD68, ILK | TSHR 4727/4885THRB 3475/4885DNM1 3309/4885 |
| US-12156954-B2 | Composition for hard tissue repair and kit for hard tissue repair | RAD51, CD68, ILK | TSHR 4727/4885THRB 3475/4885DNM1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.